As promised, we bring you the new and improved FiercePharma
by Rebecca Willumson
Many of you saw the new FierceBiotech website launch earlier this week and now I am pleased to bring you the newly redesigned FiercePharma. Our new website …
Merck's DPP-4 newcomer Marizev trails Januvia in safety: Report
by Emily Wasserman
Merck wants its new weekly diabetes treatment, Marizev, to build on the success of its blockbuster DPP-4 inhibitor Januvia. But at least when it comes to…
AbbVie, Roche look for blockbuster boost from $110K leukemia med
by Tracy Staton
There's a new leukemia drug in town, and to hear analysts tell it, Venclexta is destined to hit the blockbuster target. Developers AbbVie and Roche say…
Merck KGaA launched fertility med Luveris more than 10 years ago, but never conducted a follow-up trial required by the FDA. Now, the agency has pulled its…
Amid finger-pointing on native ad rules, pharma gears up to do it right
by Beth Snyder Bulik
Pharma needs to set its guidelines for native advertising now, experts advise, after a new study called out marketers for breaking FTC rules on labeling paid…
Pharma primed to invest in services, but will patients get the message?
by Beth Snyder Bulik
Pharma can no longer treat patient services as an add-on. They're a must-have, a new Accenture report says, and drugmakers are putting their money into…
Can the cancer moonshot help cure Big Pharma's big bad reputation?
by Beth Snyder Bulik
Vice President Joe Biden's cancer moonshot initiative has been celebrated for its exuberance and chided for its too-small budget. But InTouch Solutions…
Allergan gets Linzess marketing edge from Ironwood exec
by Carly Helfand
When Tom McCourt, chief commercial officer at Ironwood Pharmaceuticals, first met with company R&D chief Mark Currie, he had a critical question about up-…
Humira is refusing to go quietly. Even as the anti-inflammatory faces patent expiration in the U.S. later this year, AbbVie continues not only an aggressive…
